Digest Network Come funziona
Network
/
Società
Es
Non verificato

Estrella Immunopharma, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

14 comunicati stampa

Guarda tutti i comunicati
09/02/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
03/02/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Industria
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Finanza
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
04/12/2025
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Oncologia
Salute
Biologia
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
06/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
05/06/2025
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
03/06/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato azionario
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
29/05/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0